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Abstract
Colorectal cancer is the second leading cause of cancer-related death in the Western 
industrialized world. Many epidemiological studies have shown a negative association 
between colorectal cancer incidence and vitamin D levels. It has been suggested that the 
antitumoral action of 1,25(OH)
2
D
3
 in colorectal cancer relies on several mechanisms at 
the cellular level. This prompted us to evaluate expression of certain immunohistochemi-
cal markers during tumor progression in colorectal human tissue and to study for the 
first time the relationship between histological type and grade of colorectal tumors with 
the expression of these markers. The investigated markers were the ones responsible for 
apoptosis (PAK1 and p53), cell adhesion (beta-catenin), differentiation (p53), and pro-
liferation (Ki67). We also analyzed the correlation of their expression with vitamin D 
blood levels in these patients. Our results showed that the expression of these biomark-
ers increased with progression from colorectal adenomas to carcinomas. Expression of 
PAK1, beta-catenin, and p53 in the nucleus correlated with advanced stages of carci-
noma. Low vitamin D blood levels correlated with nuclear accumulation of p53, nuclear 
beta-catenin expression, and expression of Ki67.
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1. Introduction
Colorectal cancer (CRC) is one of the commonest malignancies affecting both males and 
females. It is the second leading cause of cancer-related death in the Western industrial-
ized world. The incidence of colorectal cancer increases with age, with nearly two-thirds 
of patients diagnosed aged over 65 years. Colorectal cancer (CRC) is the third most fre-
quent tumor, which affects the inhabitants of developed and developing countries. Among 
males, CRC comes after lung and prostate tumors; among females it follows breast cancer, 
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 occupying the second place in terms of incidence [1]. As a result of early detection of colonic 
polyps by screening and removal before they can develop into outright cancer, death rates 
have been dropping. In addition, screening and treatment for colorectal cancer at early stages 
have improved over the last several decades, resulting in increasing number of survivors of 
colorectal cancer.
Vitamin D is a secosteroid. Though it is named a vitamin, it is rather recognized as a prohormone 
given its synthesis in the skin and the multiple systemic actions of its metabolites [2]. In 1980, 
Garland brothers had suggested that vitamin D could be a protective factor against colorectal 
cancer, based on their observation of geographic distribution for colorectal cancer mortality in 
regions where population was less exposed to sunshine [3]. Few years later, the same authors 
confirmed this association, by reporting an inverse correlation between vitamin D status and 
CRC [4]. Different studies in the upcoming years [5–7] have also confirmed the relationship 
between plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer.
Many epidemiological studies have shown a negative association between colorectal cancer 
incidence and vitamin D levels [4, 7], as well as colorectal cancer risk and calcium intake 
[8, 9]. 1,25-Dihydroxyvitamin D3 directly affects growth factor and cytokine synthesis and 
signaling in colonic epithelium and modulates the cell cycle, apoptosis, and differentiation 
[10]. 1,25(OH)
2
D
3
 exerts its biological effects by binding to the vitamin D receptor (VDR), 
thereby regulating gene expression. The active metabolite has prominent antiproliferative, 
anti-angiogenic, and pro-differentiating action in a wide range of tumor cells due to the VDR 
being expressed in almost all tissues. Several important cellular signaling pathways can thus 
be acted upon. However, for clinical trials, the problem remains of how to administer side 
effect-free doses of 1,25(OH)
2
D
3
 [11].
A frequently measured range for serum levels of 25OHD
3
 in adults is 10–50 ng/ml. Intestinal 
calcium absorption is optimized at levels above 30–32 ng/ml. Parathyroid hormone levels 
start to rise at 25OHD levels below 30 ng/ml, marking vitamin D insufficiency [12]. Numerous 
investigations reported an increased risk for colorectal cancer in individuals with 25OHD
3
 
blood levels below 12 ng/ml [13, 14].
In kidney cells, 25OHD is converted by the hydroxylase into the active metabolite 1,25(OH)
2
D
3
. 
However, also other cell types, such as colonocytes, express vitamin D hydroxylases [15], indi-
cating an autocrine/paracrine function of the active metabolite. Low serum 25OHD
3
 precursor 
levels could result in colonic 1,25(OH)
2
D
3
 production that is insufficient for maintenance of 
autocrine/paracrine regulation of cellular growth and function [16].
It has been suggested that the antitumoral action of 1,25(OH)
2
D
3
 in colorectal cancer relies on 
several mechanisms at the cellular level, such as inhibition of cell proliferation, sensitiveness 
to apoptosis, induction of epithelial differentiation, cell detoxification metabolism, inhibi-
tion of angiogenesis, and cell-cell adhesion [2]. This prompted us to evaluate immunohis-
tochemical expression of beta-catenin and PAK1 (which are involved in Wnt-beta-catenin 
pathway) as well as expression of p53 and Ki67 (markers of apoptosis and cell prolifera-
tion, respectively) in colorectal polyps and cancer. We therefore studied for the first time the 
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 relationship between histological type and grade of colorectal tumors with the expression of 
these markers and attempted to correlate these results with vitamin D blood levels.
2. The role of vitamin D in CRC
2.1. Relevant data about CRC
Colorectal cancer develops through a multistage process of histopathologic and molecular 
changes, as a result of complex interactions between genetic predisposition and environmen-
tal factors. This type of cancer presents an ideal research model of carcinogenesis, since it 
progresses through multistep histopathologic changes and lesions of each stage are available 
for studying. Studies regarding colorectal carcinogenesis are focused on the genetic changes 
in three fundamental categories of genes: (1) tumor suppressor genes, (2) proto-oncogenes, 
and (3) DNA repair genes [17].
Comparative studies in human and animal samples have proved their similarity as organ-
isms, regarding many pathological processes, including cancer, the same cell structure, and 
the same function of organ systems. Furthermore, in favor of this similarity of human and ani-
mal organisms, an additional argument would be using the same medicines both in humans 
and animals. Moreover, a range of surgical techniques and treatments such as transplanta-
tions and surgical techniques were established and sophisticated being applied firstly in ani-
mals. Many disease developments can be investigated in animal models in physiologically 
relevant conditions with humans. Colon carcinogenesis, as widely known, is a multifactorial 
process influenced by many interactive variables, making it difficult to determine an exactly 
specified mechanism. Using animal models as an investigation approach will make possible 
in vivo molecular, pathological, physiological, and anatomical possibilities to researchers of 
animals, giving us the favor to understand many disease features.
Mouse models have served as a basis for investigations in the field of colorectal cancer etiol-
ogy as well as for mechanisms underlying the oncogenic process. On the other side, xenograft 
models are used to examine the response of the human tumor to a specific therapeutic regime. 
However, it is not clear if drug efficacy data obtained from xenograft models translate into 
clinically relevant treatment modalities.
2.1.1. Genetic changes during colorectal carcinogenesis
In colorectal cancer, it is the progressive accumulation of multiple genetic mutations, which 
results in the transition from normal mucosa to benign adenoma, to severe dysplasia, and to 
frank carcinoma [18]. More than two decades ago, Fearon and Vogelstein presented the model 
for the genetic basis of colorectal neoplasia, the adenoma-carcinoma sequence [19]. According 
to this genetic model, in most colorectal cancers, the primary event is an aberrant activation 
of APC/beta-catenin pathway, followed by RAS mutations and loss of function of p53 in later 
stages, while the total accumulation of changes, rather than their order, is responsible for 
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determining the tumor’s biologic properties. Ten years later, it was concluded that mutations 
in all three genes happen in only 6.6% of colorectal cancers, indicating that these mutations lie 
on alternate pathways of colorectal tumor development; the heterogeneous pattern of tumor 
mutations suggests that multiple alternative genetic pathways to colorectal cancer exists [20].
2.1.2. Epigenetic changes in colorectal neoplasia
In the later years, colorectal cancer development is seen from a different point of view: genetic 
alterations represent only one piece of a complicated process [21–25]. Epigenetic changes in 
cancer-related genes and noncoding RNAs also have a function which contributes to the 
malignancy status [26, 27]. Factors that may induce epigenetic changes in colorectal neoplasia 
involve environmental, as well as inherited factors:
2.1.2.1. Environmental factors
The influence of environmental factors on epimutagens most of all includes dietary factors, and 
among them folate is the most investigated in connection to colorectal neoplasia. Folate is a 
donor of one-carbon units and therefore is important in methylation reactions and in DNA syn-
thesis and repair [28]. According to epidemiological and experimental studies, dietary folate cor-
relates inversely with the risk of colorectal neoplasia [29–31]. However, the effect of folate intake 
on tumorigenesis is very complex and depends on the stage of tumor development [10, 32].
Advancing age also correlates closely with epigenetic changes in normal colorectal mucosa, 
where methylation of certain genes, including the ESR1 [33, 34], MLH1 [35], HIC1, and IGF2 
[36], has been shown to increase progressively with age. This process seems to be accelerated 
in patients with colorectal cancer, for at least some of these genes [37, 38].
2.1.2.2. Inherited factors
Given that epigenetic changes are stable and potentially heritable through meiosis, some of 
the ways in which inheritance may influence epigenetic changes associated with colorectal 
neoplasia should be considered [28]. Groups of authors have reported germline epimutations 
in MLH1, which creates predisposition to young-onset MSI tumors in colon and at extraco-
lonic sites [39, 40]. Germline epimutation provides a mechanism for phenocopying of genetic 
disease [39] and causes transcriptional silencing of the affected allele [40]. According to these 
observations, germline epigenetic changes can mimic hereditary cancer syndromes and may 
be inherited [41, 42]. The timing when these changes occur, as well as the combination of 
genetic and epigenetic events, rather than their merely accumulation, gives selective priority 
to the cancer cells, resulting in activation of certain pathways [43].
2.1.3. Clinical relevance of epigenetic changes in colorectal cancer
Increasing recognition of epigenetic changes in the histologically normal colorectal mucosa 
and in precursor lesions can make these changes serve as a marker for patients at risk for 
colorectal cancer [33]. Epigenetic markers are progressively finding their place in screening 
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tests for colorectal neoplasia [44]. Regarding the impact that epigenetic changes may have in 
colorectal cancer treatment decisions, there is a growing evidence that MSI tumors respond 
differently to traditional chemotherapeutic agents [45, 46]. Moreover, the outcomes for some 
patients with these cancers may be worse with standard treatments [47].
It was observed that low folate status predisposes to development of several malignancies 
including colorectal cancer [48]. Experimental studies confirmed that older age and inade-
quate folate intake are strongly implicated as important risk factors for colon cancer and each 
is associated with altered DNA methylation [49]. Keyes and colleagues concluded that folate 
supplementation, which can enhance methyl availability, increases both genomic DNA meth-
ylation and p16 promoter methylation in old mice; this epigenetic change by aging and dietary 
folate affects the expression of p16, a critical gene for both aging and carcinogenesis [49]. 
Methylation/demethylation processes in promoter sequences of vitamin D hydroxylases may 
lead to reduced or enhanced expression of these enzymes, respectively [50] (see Section 2.3.3.).
Numerous studies have provided evidence that women may be better protected against 
colorectal cancer than men. Several investigations have reported a lowered colorectal cancer 
risk associated with enhanced phytoestrogen intake (see, e.g., [51]). Phytoestrogens resemble 
structurally and act functionally as estrogen agonists; their affinity for ER-β is higher than that 
of estradiol itself and is lower for ER-α [52]. Therefore, phytoestrogens can act as estrogen 
agonists or antagonists depending on the type of estrogen receptors available, as well as on 
the level of endogenous circulating hormones [53, 54]. In Asian countries, populations with 
high consumption of soy foods (which are very rich in phytoestrogens) have a clearly reduced 
risk of colorectal cancer incidence. The major phytoestrogen in soy—genistein—beside other 
mechanisms (see Section 2.3.4.) is also involved in regulation of gene activity by modulating 
epigenetic events such as DNA methylation and/or histone acetylation.
2.2. Vitamin D: general concepts
Bound to the vitamin D receptor (VDR), 1,25(OH)
2
D
3
 not only regulates calcium and phos-
phate metabolism but also exerts a wide range of non-calcemic biological effects, the most 
important of which are suppressing hyperproliferative growth and supporting cell differenti-
ation [16]. When Zehnder and coworkers demonstrated that many types of cells were positive 
for CYP27B1, it was recognized that there is a widespread potential for extrarenal synthesis of 
1,25(OH)
2
D
3
 [55]. Further, Cross and coworkers demonstrated the synthesis and degradation 
of 1,25(OH)
2
D
3
 by high-pressure liquid chromatography [56], and it was accepted that vita-
min D could have alternative roles in extrarenal tissues, for instance, in the colon.
2.2.1. VDR in normal and in malignant colon cells
Vitamin D actions as a steroid hormone are mediated through the vitamin D receptor (VDR) 
[57], which is a high affinity ligand-activated transcription factor [58]. Activated VDR het-
erodimerizes with the retinoid X receptor (RXR); this complex binds to the vitamin D response 
elements (VDREs) in the promoter of target genes and recruits coactivators and corepressors 
to induce or inhibit gene transcription [59]. The expression and functionality of the VDR are 
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mandatory for the anticancer effects of vitamin D; therefore, the loss of this transcription fac-
tor, as seen in some cells after malignant transformation, results in calcitriol resistance [58].
An important step toward understanding of the complexity of vitamin D interactions was 
recognition of the fact that VDR is also expressed in tissues other than those responsible for 
calcium and phosphorus metabolism. The presence of VDR in malignant cells suggested that 
regulation of cancerous cell functions could be another target of 1,25-(OH)
2
D
3
 and provided 
the biological basis for many epidemiological studies. Shabahang et al. reported that the more 
differentiated is the cell line, the expression of VDR is higher [60]. Cross and coworkers found 
that expression of the VDR increases during transition from normal mucosa to polyps, as well 
as in the course of progression from adenomas to well-differentiated and moderately differen-
tiated tumors, and then declines during further progression [61]. This suggests that cancerous 
colon cells express VDR until they reach a certain level of differentiation. Such model of regu-
lation suggests existence of a physiologic protective mechanism of tumor progression, which 
is reduced in the later stages. Investigations by Evans and coworkers found that in colorectal 
cancer, a high level of VDR expression was associated with a favorable prognosis [62].
VDR can function as a receptor for secondary bile acid, lithocholic acid, which is a hepatotoxic 
compound and a potential enteric carcinogenic [63]. Binding of both lithocholic acid and vita-
min D to the VDR results in induction of CYP3A, the enzyme that detoxifies lithocholic acid 
in the liver and intestine [7, 64].
2.2.2. Expression of VDR, CYP27B1, CYP27A1, and CYP24 as a function of malignant 
transformation in the colon
Cross et al. [56] were the first to demonstrate the conversion of the precursor 25 OH D
3
 into 
1,25(OH)
2
D
3
 in Caco-2 cells by finding constitutive expression of the CYP27B1 in almost every 
growth phase of this cell line and the sequential metabolism of the secosteroid along the C-24 
and C-23 oxidative pathways. The authors concluded that human colon cells can control their 
growth through 1,25(OH)
2
D
3
 in an autocrine/paracrine manner dependent upon the pres-
ence of the vitamin D receptor [56]. Cross and coworkers were also the first to demonstrate 
that expression of CYP27B1 and of the VDR rises (approximately fourfold) in the course of 
progression from adenomas to well-differentiated and moderately differentiated (G1 and G2) 
tumors and then substantially declines during further progression [65]. Other authors also 
reported that in hyperproliferative, premalignant colon cells, expression of CYP27B1 (synthe-
sizing hydroxylase) is increased, as well as VDR expression, while in high-grade colon tumors, 
CYP27B1 expression is again repressed (in contrast with CYP24A1—degrading hydroxylase 
expression) [15]. According to this, the extrarenal synthesis of 1,25(OH)
2
D
3
 provides a physi-
ological mechanism for prevention of malignant growth.
Holt and coworkers [66] demonstrated for the first time that rectal crypt proliferation cor-
related inversely with serum 1,25(OH)
2
D
3
 levels. These data support the abovementioned 
hypothesis that colon cancer cells posses an intrinsic physiological defense which can pre-
vent hyperproliferation and progression into malignancy [56]. In colon tissue derived from a 
large patient cohort, VDR and CYP27B1 mRNA expression was low in normal tissue but rose 
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early during colon tumor progression [65, 67]. This system fails in the late stage, high-grade 
colon cancer, while there is increased expression of CYP24, which could cause rapid catabo-
lism of 1,25(OH)
2
D
3
 at the tumor site, counteracting its local inhibition of tumor growth [68]. 
Physiologic regulation of vitamin D hydroxylases in normal and malignant human colonic 
tissue suggests a role for the locally accumulated hormone in prevention of tumor progres-
sion; during low-grade early-stage malignancy, colonic synthesis of 1,25(OH)
2
D
3
 could poten-
tially provide a block to progression, if its catabolism could have inhibited [69].
2.2.3. Epigenetic regulation of vitamin D hydroxylases
Expression of CYP27B1 and CYP24A during colorectal cancer progression is under epigen-
etic control [16]. Differences in expression of vitamin D hydroxylases during tumor progres-
sion, as seen in colorectal cancer patients [65, 68], could be caused by epigenetic regulation 
of gene activity through methylation/demethylation processes, as well as histone acetylation/
deacetylation [16]. DNA methylation at CpG islands in the promoter region of genes is associ-
ated with transcriptional silencing of gene expression in mammalians, whereas reduction of 
methylation in CpG islands results in increase of gene activity.
In low-grade cancer, CYP27B expression is very high, comparing with its expression in 
colorectal mucosa of non-tumor patients [15, 65]. Increased synthesis of 1,25(OH)
2
D
3
 in colon 
mucosa could be responsible for higher transcriptional activity of CYP24A1, as well as for 
autocrine/paracrine inhibition pf tumor cell growth. If transcriptional repression of CYP24A1 
expression could be affected by methylating agents, advanced colorectal cancer patients could 
also benefit from treatment with vitamin D substances [10].
2.2.4. The antitumoral action of 1,25(OH)
2
D
3
 in different tissue types
Numerous observations have indicated a much broader range of action for 1.25(OH)
2
D
3
, includ-
ing the regulation of cell differentiation, proliferation, apoptosis, invasion, and angiogenesis 
in several types of tumor cells and animal models of cancer [70–72]. 1-Alpha,25(OH)
2
D
3
, also 
known as calcitriol, as well as vitamin D analogs, might have potential as anticancer agents 
because their administration has antiproliferative effects, can activate apoptotic pathways, 
and inhibit angiogenesis [70]. A general deregulation of the vitamin D system was observed 
in most malignancies. Evidence for an inverse correlation between serum vitamin D
3
 status 
and cancer incidence, e.g., the colon, breast, and prostate, has increased over the last years 
[73]. Anticancer property of vitamin D has been studied in a wide variety of commonly occur-
ring cancers (both in vitro and in vivo) of which the actions on colorectal, breast, and pros-
tate cancers have been found to be most promising [74]. In 16 types of cancer, there is an 
evidence of a beneficial role of vitamin D (gastrointestinal: colon, esophageal, gallbladder, 
gastric, pancreatic, and rectal; urogenital: bladder, kidney, and prostate; female: breast, ovar-
ian, and vulvar cancer; and blood cancers: Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, 
and multiple myeloma) [75]. A strong association between a low vitamin D status and cancer 
incidence or mortality has been reported for colon, rectal, breast, prostate, and ovarian cancer 
[76]. However, data regarding the role of vitamin D in cancer risk, incidence, and mortality 
are still controversial [58].
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2.3. Mechanisms of colorectal cancer: vitamin D interaction
The molecular basis of the idea that vitamin D has the potential to prevent cancer lies in its 
role as a nuclear transcription factor, which regulates cell growth, differentiation, apoptosis, 
and many cellular mechanisms, with a key role for cancer development.
2.3.1. Effects of vitamin D on cell proliferation, differentiation, apoptosis, and angiogenesis
Since the 1980, 1,25-OHD
3
 has been recognized as a potent cellular antiproliferative and pro-
differentiating agent in the colon [69]. During the last two decades, vitamin D was proven as 
a potential inhibitor of cell growth and angiogenesis, as well as a stimulator of cell maturation 
and apoptosis [70]. The classic signaling pathway is through the vitamin D nuclear receptor 
(VDR), which is a transcription factor.
Over recent years there has been an expanding consideration for non-calcemic functions of 
1,25(OH)
2
D
3
, including its antitumoral effects [73]. There is an increasing evidence about 
inverse correlation of vitamin D status and colorectal, breast, and prostate cancer [6, 75, 77]. 
Moreover, many observational studies have reported various actions of 1,25(OH)
2
D
3
, as regu-
lation of cell differentiation, proliferation, apoptosis, cell invasion, and angiogenesis; vitamin 
D exerts its actions mainly via its high affinity receptor VDR through a complex network of 
genomic (transcriptional and posttranscriptional) and also nongenomic mechanisms, which 
are partially coincident in the different cells and tissues studied [70–72].
Angiogenesis is an essential process for growth of solid tumors; therefore, anti-angiogenic 
agents contribute to the anticancer treatment. Anti-angiogenic drugs can cause inhibition of 
tumor progression, stabilization of tumor growth, and regression of tumor mass and prevent 
metastases. Experimental studies have reported anti-angiogenic action of 1,25(OH)
2
D
3
, as well 
as his analog, 22-oxacalcitriol [78]. Today, there is a growing evidence that high vitamin D 
intake and a plasma level of 25(OH) D
3
 reduce the incidence of colorectal cancer by modifying 
cancer angiogenesis, cell apoptosis, differentiation, and proliferation. Results from Kang et al. 
[79] suggest that vitamin D supplementation alone, or in combination with anticancer agents, 
might reduce the incidence of colorectal cancer.
Vitamin D also increases the level of cystatin D—an endogenous protein, which shows antitu-
mor and antimetastatic property, by facilitating the expression of the gene coding for it [74].
Induction of apoptosis is a mechanism by which 1,25(OH)
2
D
3
 inhibits tumor cell growth and 
may contribute to tumor suppression and explain the reduction in tumor volume found in vari-
ous in vivo animal studies [63]. Besides its physiological function in maintaining constancy of 
cell numbers in different tissues, apoptosis also prevents the possibility of mutational changes 
leading to malignancy after DNA damage by removal of such damaged cells [74]. 1,25(OH)
2
D
3
 
is able to modulate apoptosis mediators by diverse mechanisms that favor the elimination of 
malignant cells [58]. Apoptosis sensitization by vitamin D in colorectal adenoma and carcinoma 
cells involves the upregulation of the proapoptotic proteins and the downregulation of anti-
apoptotic proteins. The proapoptotic BAX component of the Bcl-2 competes with the antiapop-
totic Bcl-2 on mitochondrial cell surface for release of cytochrome c from it; the proapoptotic 
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branch tends to stimulate the release, while the antiapoptotic branch inhibits it. In normal cells, 
survival factors continuously oppose apoptosis by several mechanisms, out of which activation 
of antiapoptotic Bcl-2 is important. Proapoptotic compounds may have a favorable role in the 
prevention of cancer development, growth, and metastasis while aiding to its chemotherapy 
[74]. Vitamin D may also induce cell death by alternative pathways, such as increasing the cal-
cium concentration, releasing cytochrome c and reducing intracellular glutathione [58].
Our study summarizes changes in the expression of certain immunohistochemical markers 
during tumor progression in colorectal human tissue. We have investigated markers respon-
sible for apoptosis (PAK1 and p53), cell adhesion (beta-catenin), differentiation (p53), and 
proliferation (Ki67), as well as correlation of their expression with vitamin D blood levels [80].
In our study, average vitamin D blood level in patients with colorectal cancer was 5.99 ng/ml 
(range: 3–23.04 ng/ml), whereas average vitamin D blood level in patients with colorectal ade-
noma was much higher, i.e., 21.4 ng/ml (range: 11.3–30.66 ng/ml). The difference was statisti-
cally highly significant (p = 0.0001). Interestingly, among our patients with adenocarcinoma, 
only one had a vitamin D blood level in a normal range (23.04 ng/ml), while only one adenoma 
patient approached vitamin D deficiency (11.3 ng/ml).
PAKs are a family of serine/threonine protein kinases with six isoforms (PAK1-6), which play 
important roles in cytoskeletal dynamics, cell survival, and proliferation [81]. Although PAKs 
are not mutated in cancerogenesis, they are overexpressed, hyperactivated, or amplified in 
several human tumors. PAK1 has been reported to be overexpressed in colorectal cancer, but 
its role in CRC remains unclear [82]. Some recent studies have implicated PAK’s role in acti-
vation of Wnt-beta-catenin signaling through direct interaction and phosphorylation of beta-
catenin (see, e.g., [83]). In colorectal cancer, nuclear PAK1 is associated with advanced tumor 
stage. In adenocarcinomas, overall PAK1 (nuclear and cytoplasmic staining) was expressed in 
80% of cases. Nuclear PAK1 expression was negative in all adenomas, as well as in grade I ade-
nocarcinomas. In grade II adenocarcinomas, nuclear PAK1 was expressed in 20% of patients, 
while in grade III adenocarcinomas, it was expressed in 50% of cases (Figure 1). Our results 
of PAK1 expression were similar to those from Ye [81] and Zhu et al. [84], who found PAK1 
expression in 70% of cells. Correlations with tumor grade and stage, as well as with the nodal 
status [85], indicate PAK1 as a very important marker during colorectal tumor progression.
Figure 1. PAK1 expression in (a) colorectal mucinous adenocarcinoma (nuclear expression), (b) colorectal polyp (no 
expression), and (c) colorectal non-mucinous adenocarcinoma (cytoplasmic expression).
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Numerous studies have focused on the clinical relevance of nuclear beta-catenin accumu-
lation during colorectal pathogenesis, demonstrating its diagnostic, as well as prognostic 
significance [86]. A high density of beta-catenin nuclear accumulation was associated with 
higher mortality in selected groups of patients with colorectal cancer [87]. Under normal cir-
cumstances, beta-catenin is part of a complex of proteins that constitute adherens junctions 
necessary for creation and maintenance of epithelial cell layers, but the gene that codes for 
beta-catenin can function as an oncogene as well. When beta-catenin binds to the product of 
the mutated APC gene, free cytoplasmic beta-catenin is destabilized. This leads to the accu-
mulation of nuclear beta-catenin, where it acts as a transcriptional activator of genes, spe-
cific for tumor formation [88]. Aberrant activation of the Wnt/beta-catenin signaling pathway 
due to mutation of adenomatous polyposis coli (APC), of beta-catenin or AXIN genes, is the 
most common and initial alteration in sporadic colorectal tumors [89]. It is significant that 
reduction of beta-catenin transcriptional activity is known to be mediated by 1,25(OH)
2
D
3
 
and is accompanied by the export of nuclear beta-catenin and its relocalization to the plasma 
membrane [90]. Our study showed a significant increase in beta-catenin nuclear expression 
during progression from adenomas to non-mucinous adenocarcinomas, as well as from non-
mucinous adenocarcinomas to mucinous adenocarcinomas (Figure 2).
Normal colorectal mucosa (tumor margins) expressed membranous beta-catenin staining and 
was used as internal positive control (Figure 3). In contrast to results of some other authors [91], 
we found beta-catenin overexpression to be most pronounced in mucinous adenocarcinomas. 
Nuclear beta-catenin expression correlated with both tumor grade and stage. Cytoplasmic beta-
catenin expression was present in most of polyps and in all non-mucinous adenocarcinomas, 
whereas staining was positive in only 25% of mucinous adenocarcinomas. Cytoplasmic beta-
catenin expression showed an association with better differentiation. This observation corre-
lates with results from other authors. The presence of beta-catenin expression in the membrane 
and cytoplasm at an early tumor stage, and nuclear expression at advancing stages, illustrates 
the sequence of genetic mutations in normal epithelium developing into colorectal tumors.
p53 is a nuclear protein that induces cell cycle arrest or apoptosis in response to DNA dam-
age. Its mutations are frequently associated with colorectal oncogenesis. The wild type of 
the p53 gene product has a short half-life and is not detectable by IHC. In contrast, mutant 
Figure 2. Beta-catenin expression in (a) mucinous adenocarcinoma (nuclear expression), (b) adenomatous polyp 
(membranous expression), and (c) non-mucinous adenocarcinoma (cytoplasmic expression).
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p53 protein has a much longer half-life, accumulates in the nucleus, and creates a stable tar-
get for IHC detection [92]. Frequency of p53 expression in our study correlates well with 
the frequency of p53 mutations found in studies using sequencing techniques for identifica-
tion of p53 mutations in sporadic colorectal cancer [93, 94]. We detected nuclear p53 expres-
sion in 53% of adenocarcinoma patients, while cytoplasmic expression was present in 33% 
(Figure 4). In other studies the frequency of p53 staining ranges from 45 to 60% [95]. Nuclear 
p53 expression was increasing in parallel to tumor grade: in grade III adenocarcinomas, p53 
was expressed in all cases, in grade II adenocarcinomas, p53 was expressed in 50% of cases, 
and in grade I adenocarcinomas, nuclear p53 was expressed in 33% of cases. In the group with 
colorectal adenomas, only one patient had nuclear p53 expression.
Ki67 is a nuclear nonhistone protein that is present at low levels in quiescent cells but is 
increased in proliferating cells, especially during G2, M, and the latter half of the S phase. 
Thus, Ki67 reactivity, defined as percentage of tumor cells staining positive in IHC staining, is 
a specific nuclear marker for cell proliferation. While the growth of malignant tumors is highly 
variable (although it might reflect their clinical course), proliferation still is a key feature of 
tumor progression. In our study, the mean Ki67 expression in all colorectal adenocarcinomas 
Figure 3. Membranous expression of beta-catenin in the margins of colorectal carcinoma: (a) mucinous adenocarcinoma 
and (b) non-mucinous adenocarcinoma.
Figure 4. p53 expression in (a) mucinous adenocarcinoma (nuclear expression), (b) non-mucinous adenocarcinoma 
(nuclear and cytoplasmic expression), and (c) adenomatous polyp (no expression).
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was 47%. This is similar to those of Georgescu et al. (48%) [96] and Oshima et al. (44%) [97]. 
The proliferative activity as measured by Ki67 antibody was related to histological type and 
grade: Ki67 expression was higher in non-mucinous adenocarcinomas, compared with muci-
nous adenocarcinomas (p = 0.0164) (Figure 5a and b).
Ki67 expression was high in well-differentiated (G1) and moderately differentiated (G2) 
adenocarcinomas (52%), compared with poorly differentiated (G3) adenocarcinomas (17%) 
(p = 0.0314). In colorectal adenomas, Ki67 expression was very low (16%) (Figure 5c). This 
indicates a low level of proliferative activity in these lesions. While our results are similar to 
those published by Nabi et al. [98], Georgescu et al. observed that Ki67 expression was higher 
in poorly differentiated (57%) than in moderately differentiated (34%) and well differenti-
ated (20%) adenocarcinomas [96]. Correlation of Ki67 expression with the histological type of 
adenocarcinoma resulted in 26% in mucinous versus 55% in non-mucinous colorectal adeno-
carcinomas and was similar to that reported by Nabi et al. [98]. This suggests that proliferative 
activity in mucinous adenocarcinomas is lower than in non-mucinous adenocarcinomas.
Taken together, our data show that expression of these biomarkers increased with progres-
sion through the adenoma to carcinoma sequence. Accumulation of PAK1, beta-catenin, and 
p53 in the nucleus revealed correlation with advanced stages. Ki67 expression, however, was 
higher in well-differentiated than in poorly differentiated carcinomas.
Serum vitamin D levels in patients with positive nuclear PAK1 and beta-catenin expression 
had a negative trend, while patients with positive nuclear p53 expression had significantly 
lower vitamin D blood levels. Vitamin D levels were the lowest in mucinous adenocarcinoma 
and correlated with nuclear accumulation of p53, nuclear beta-catenin expression, and higher 
expression of Ki67. Considering the importance of an adequate 25OHD
3
 supply for synthesis 
of the active metabolite 1,25(OH)
2
D
3
 in colon mucosal cells and the relevance of the latter for 
regulation of the Wnt/beta-catenin pathway, 25OHD
3
 blood levels could be considered as 
an indicator of Wnt/beta-catenin activity and increased cell proliferation [80]. This further 
emphasizes the chemopreventive role of vitamin D in CRC.
Garland et al. [99] in the early 1999 had suggested that ingestion of at least 800 IU (20 μg) of 
vitamin D, together with 1800 mg of calcium, is needed to significantly lower the incidence 
Figure 5. Ki67 expression in (a) mucinous adenocarcinoma (25%), (b) non-mucinous adenocarcinoma (70%), and (c) 
adenomatous polyp (10%).
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and mortality of colorectal cancer. Matusiak and Benya concluded that nontoxic vitamin D 
precursors should be sufficient for CRC chemoprevention, but that neither vitamin D nor its 
precursors may be sufficient for CRC chemotherapy [100].
2.3.2. The expression of VDR and CYP27B1 in carcinogenesis and at the time of Vitamin D therapy
Sufficient blood levels of vitamin D provide a substrate for increasing the amount of vitamin D 
in the colonocytes, due to the presence of VDR and CYP27B1. Cross et al. [65] had shown (by 
RT-PCR, as well as by Western blotting and immunohistochemical methods) that in human 
large intestinal carcinomas expression of the genes encoding the 25-(OH)D
3
-1α-hydroxylase 
(CYP27B1), as well as the VDR, increases in parallel with ongoing dedifferentiation in the 
early phase of carcinogenesis, whereas in poorly differentiated late-stage carcinomas, only 
low levels of the respective mRNAs can be detected [65]. According to this finding, colorectal 
cancer cells are able to increase their autocrine counter-regulatory response to neoplastic cell 
growth, through upregulation of the vitamin D/VDR system which mediates the antimitotic 
effects of the steroid hormone.
Expression of VDR, CYP27B1, and CYP24 determines the efficacy of the antimitotic action of 
1,25-D3 and is distinctly related to the degree of differentiation of cancerous lesions. Bareis et 
al. [67] addressed the question of whether the effects of 1,25-D3 on VDR, CYP27B1, and CYP24 
gene expression in human colon carcinoma cell lines also depend on the degree of cellular 
differentiation [67]. They showed that slowly dividing, highly differentiated Caco-2/15 cells 
responded in a dose-dependent manner to 1,25-D3 by upregulation of VDR and CYP27B1 
expression, whereas in highly proliferative, less differentiated cell lines, such as Caco-2/AQ 
and COGA-1A and COGA-1E, negative regulation was observed. From the observed clonal 
differences in the regulatory effects of 1,25-D3 on VDR and CYP27B1 gene expression, the 
authors suggest that VDR-mediated growth inhibition by 1,25-D3 would be efficient only in 
highly differentiated carcinomas.
Bises et al. double stained colon tumors for CYP27B1 and VDR [15]; they found CYP27B1-
enhanced expression in high- to medium-differentiated human colon tumors compared with 
tumor-adjacent normal mucosa or with colon mucosa from non-cancer patients. In high-grade 
undifferentiated tumor areas, expression was lost. Most colonocytes expressed both CYP27B1 
and VDR, while some of them were positive only for VDR; this suggests that 1,25-D3 synthe-
sized in colonocytes and bound to its receptor could exert its antimitotic function in both an 
autocrine and a paracrine fashion [15].
Because (as Matusiak and Benya [100] had shown) CYP27B1 is present in colonic epithe-
lia, D3 alone may be sufficient for CRC chemoprevention and/or chemotherapy, providing 
that CYP27A1 and CYP24 are present in appropriate quantities and cellular compartments. 
To determine whether cholecalciferol may be useful for CRC chemoprevention and/or che-
motherapy, Matusiak et al. reported on cellular CYP27A1 and CYP24 protein expression in 
human ACFs, polyps, and CRCs of defined differentiation along with associated lymph node 
metastases. Their findings suggest that cholecalciferol has potential for use in CRC chemopre-
vention but may be less efficacious for CRC chemotherapy.
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2.3.3. Interactive role of calcium and vitamin D in colorectal prevention
Combined supplementation is required for optimal chemoprevention of cancer by calcium 
and vitamin D [76]. An interaction between nutritional calcium and vitamin D in protection 
against colorectal cancer may be due to the ability of luminal calcium to suppress degradation 
of 1,25(OH)
2
D
3
 synthesized in colonocytes [101]. Calcium may also directly reduce hyperpro-
liferation of the colonic mucosa [102] by binding to the calcium-sensing receptor (CaR) and 
by activating antimitotic, proapoptotic signal transduction mechanisms [103–105]. The effects 
of vitamin D and calcium on growth and differentiation of many epithelial cancers may be 
explained, in part, by their ability to control expression of E-cadherin and to regulate Wnt path-
way [106]. Calcium regulates Wnt signaling through the calcium-sensing receptor as well: acti-
vation of the CaR enhances E-cadherin expression and suppresses TCF4 expression [107, 108]. It 
also stimulates secretion of Wnt5a, which inhibits beta-catenin signaling by increasing expres-
sion of an ubiquitin ligase that is involved in degradation of beta-catenin [109].
Several studies implied that the beneficial effect of calcium supplementation was due to the 
ability of calcium to form insoluble salts with potentially irritating and ultimately tumori-
genic bile acids [110]. However, bile acids also interact with the vitamin D system: LCA is 
able to bind the VDR, thereby stimulating expression of CYP24A1 [111] and reducing avail-
ability of locally synthesized colonic 1,25(OH)
2
D
3
. Bile acids are able to induce aberrant crypt 
foci, the precursors of neoplastic transformation in the colon; LCA activates the pregnane 
X receptor (PXR) and induces CYP3A expression [10]. In addition, bile acids interact with 
the vitamin D system: lithocholic acid can bind to the vitamin D receptor (VDR) and induce 
CYP24A1 expression [111].
Ingestion of considerable amounts of calcium and soy (phytoestrogens—see Section 2.3.4.) 
could provide accumulation of 1,25-OH
2
D
3
 in colon, by enhancing the expression of synthe-
sizing hydroxylase (CYP27B1) and reducing of the catabolizing hydroxylase (CYP24A). This 
is not the case with the renal vitamin D hydroxylases.
2.3.4. Role of folates in modulating the risk of colorectal cancer
As a vitamin of the B family, folate is essential for synthesis, repair, and methylation of DNA, 
while as a methyl donor, folate could play an important role in epigenetic regulation of gene 
expression [112].
The evidence from epidemiologic, animal, and human studies strongly suggests that folate 
status modulates the risk of developing cancers in selected tissues, the most notable of which 
is the colorectum [48]. Dietary folate influences DNA methylation, synthesis, and repair, and 
aberrations in these DNA processes may enhance carcinogenesis, particularly in rapidly pro-
liferative tissues such as the colorectal mucosa [113]. Folates serve as physiological methyl 
donors during nucleotide precursor biosynthesis as well as during DNA, RNA, and protein 
methylation. Therefore, changes in folate metabolism have impact on two important determi-
nants of carcinogenesis: on genetic expression and on maintenance of DNA integrity and sta-
bility. Folate deficiency affects the expression of key genes that are related to cell cycle control, 
DNA repair, apoptosis, and angiogenesis in a cell-specific manner [114]. Folate status affects 
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several cancer-related pathways including the p53 pathway, the Rb pathway, and the APC/Wnt 
pathway, as well as pathways involved in cell adhesion and cell migration and invasion [115].
Experimental results from Cross and coworkers suggest that, at least in mice, a “Western 
diet” resembling the high fat, low vitamin D, and calcium diet causes degradation of colonic 
1,25(OH)D
3
, which can be stopped only by folate optimization [101]. The authors also con-
cluded that folate optimization overrides the negative effects of low vitamin D and calcium 
intake [101]. (Regarding epigenetic regulation of vitamin D hydroxylases, see Section 2.2.3.)
According to results from Kim [116], dose and timing of folate intervention are critical in pro-
viding safe and effective chemoprevention; exceptionally high supplemental folate levels and 
folate intervention after microscopic neoplastic foci are established in the colorectal mucosa 
and promote, rather than suppress, colorectal carcinogenesis. Therefore, a “dual-modulator” 
role was suggested for folate in colorectal cancer, with a protective influence when ingesting 
only moderate amounts before development of aberrant crypt foci [117].
Extrarenal actions of 1,25(OH)
2
D
3
, such as regulation of cell differentiation, proliferation, 
apoptosis, invasion, and angiogenesis in several types of tumor cells [70–72] suggest its 
potential therapeutic role against cancer. Nevertheless, the use of 1,25(OH)
2
D
3
 is restricted 
by its hypercalcemic effect at therapeutic doses; this can be putatively overcome by the use of 
analogs that retain the antitumoral action but have less calcemic effect [2]. Numerous stud-
ies have shown that 1,25(OH)
2
D
3
 and several analogs clearly reduce the growth of colorectal 
xenografts [70, 71].
In order to prevent premalignancies as well as their progression to tumors, we should focus on 
increasing the efficiency of the vitamin D system [16]. Especially in the colon, this can be accom-
plished by consuming calcium, soy, and folate [10]. Dietary modulation (using calcium, folate, 
and phytoestrogens) of extrarenal 1,25(OH)
2
D
3
 synthesis in organs that are potentially prone to 
tumor incidence could lead to improved apoptotic and antimitotic activity by locally enhanc-
ing the concentration of 1,25(OH)
2
D
3
 in these tissues, thereby preventing tumor cell growth 
[16]. A low folate status predisposes to development of several common malignancies includ-
ing colorectal cancer [48]. Giovannucci et al. [30] demonstrated that prolonged intake of folate 
above currently recommended levels significantly reduced the risk of colorectal cancer [30].
Differences observed in the expression of vitamin D hydroxylases in patients with colon can-
cer during the course of tumor progression could be caused by the epigenetic regulation 
of gene activity via methylation/demethylation processes as well as by histone acetylation/
deacetylation [16]. Methylation/demethylation processes (i.e., epigenetic regulation) in pro-
moter sequences of vitamin D hydroxylases may lead to reduced, respectively, enhanced 
expression of these enzymes [50]. CYP27B1 expression is exceedingly high in low-grade 
cancerous lesions, compared with its expression in normal colonic mucosa of non-cancer 
patients [15]. Enhanced synthesis and accumulation of 1,25(OH)
2
D
3
 in colonic mucosa could 
be responsible for the upregulation of transcriptional activity of CYP24A1 and also for the 
autocrine/paracrine inhibition of tumor cell growth [65]. Cross et al. [16] suggested that this 
enhanced expression of CYP27B1 could be due, at least in part, to epigenetic regulation (i.e., 
demethylation), while raised CYP24A1 expression may result from the normal regulatory 
Vitamin D and Colorectal Carcinogenesis
http://dx.doi.org/10.5772/67397
119
loop  following the accumulation of 1,25(OH)
2
D
3
 in colonic mucosa [16]. However, in highly 
malignant tumors, an efficient antimitogenic effect by 1,25(OH)
2
D
3
 is unlikely, since the 
expression of the catabolic vitamin D hydroxylase by far exceeds that of CYP27B1 [68].
2.3.5. Estrogen pathway in CRC: interaction with vitamin D
Worldwide, colorectal cancer has a higher incidence rate in men than in women, suggesting 
a protective role of sex hormones in the development of disease [118]. In addition, studies 
from relationship between gender and mortality of colorectal cancer show lower mortality 
for women, especially premenopausal women; epidemiologic studies over several decades 
suggest a decline in mortality of women attributed to the use of hormone therapy [119, 120]. 
Expression of estrogen receptor (ER) subtypes α and β has been detected in cancer cell lines. 
The ER-α:ER-β ratio has been identified as a possible determinant of the susceptibility of a 
tissue to estrogen-induced carcinogenesis [10]. In both normal and cancerous colonocytes, 
ER-α expression levels remain low, while ER-β is the predominant ER in the normal colon 
[121, 122]. The expression level of ER-β in tumor tissue compared with normal colon mucosa 
is decreased and correlates with stage of the disease [123, 124].
In the colon adenocarcinoma-derived cell line Caco-2, which is ER-β positive but negative for 
ER-α, Lechner et al. demonstrated an increase of CYP27B1 after treatment with 17β-estradiol 
[125]. They proved that supraphysiological concentrations of 17β-estradiol not only elevated 
CYP27B1 mRNA expression and enzymatic activity but also reduced that of CYP24A1 [125]. By 
enhancing vitamin D accumulation in colon cancer cells, this could inhibit tumor progression. 
Transfection of SW480 cell lines with ER-β resulted in inhibition of proliferation and cell cycle 
arrest; SW480 xenografts with ER-β expression had 70% reduction in the tumor weight [126]. 
Transfection of colon cancer cell lines with ER-β also affects the MAPK signaling pathway [127].
In animal models the transcriptional activity of ERs changes over time and is influenced by 
estrogen level [128]. Therefore, it is likely that hormone replacement therapy (HRT) in women 
protects against colon cancer through an increased ratio of ER-β [118].
Regarding potential mechanisms for the interaction of estrogen with vitamin D on CRC risk, 
experimental evidence indicates that estrogen and vitamin D complexes undergo competitive 
binding for their common cellular uptake membrane receptor, megalin [129]. Megalin serves 
as a key endocytosis cell surface receptor for several vitamins and hormonal ligands (includ-
ing vitamin D [130] and its recently identified ligands—estrogen and testosterone bound to 
sex hormone-binding globulin (SHBG) [131]. This is clinically relevant to the Women’s Health 
Initiative (WHI) trial findings, as megalin gene knockout has been demonstrated to strongly 
induce both estrogen deficiency and vitamin D deficiency [131, 132].
Both estrogens and phytoestrogens exert their effects on target cells by genomic and nonge-
nomic mechanisms [133]. Phytoestrogens reduce cell injury and DNA damage mediated by 
5 μM oleic acid hydroperoxides in Caco-2 cells [134] and decrease levels of oxidative DNA 
damage in humans [135]. Genistein, a major phytoestrogen in soy, is antimitotic and proapop-
totic in colon cells via the TGF-β/Smad pathway [136]. This phytoestrogen is also involved in 
regulation of gene activity by modulating epigenetic events such as DNA methylation and/or 
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histone acetylation (see, e.g., [137]). According to experimental studies, genistein enhances VDR 
expression in colon cancer cells; upstream and downstream events in the signaling cascade are 
all interrelated and all participate in the control of VDR expression by 17β-estradiol as well as 
by phytoestrogens [138]. Genistein also induces CYP27B1 and reduces CYP24A1 expression 
and activity in a mouse model and in human colon adenocarcinoma-derived cell lines [139].
Reduced incidence of cancer (including colon tumors) has been related to the consumption of 
a typical Asian diet containing soy; soy and red clover are important sources of phytoestro-
gens that bind preferentially to estrogen receptor-beta (ER-β) [16]. While the colon cannot be 
considered an estrogen-dependent tissue, it must be defined as an estrogen-responsive organ 
[112]. Expression of estrogen receptor (ER) subtypes α and β has been detected in cancer cell 
lines. In normal colonic mucosa, it is ER-β that is mainly expressed. When mice were fed a 
diet containing soy, the expression of the synthesizing vitamin D hydroxylase, CYP27B1, was 
enhanced, and that of the catabolic hydroxylase, CYP24A1, was decreased [50]. In a clinical 
pilot trial [140], postmenopausal women with a past history of rectal adenomas were given 
a daily dose of 17 β-estradiol for 1 month to reach premenopausal hormone levels. Rectal 
biopsies were obtained at the beginning and end of the trial. A predominant result was that 
VDR mRNA was increased. Such data suggest a protective role of female sex hormones, par-
ticularly of estrogens, against CRC. This could provide a rationale for the observation that the 
age-adjusted risk for CRC is lower for women than for men, even though men and women 
suffer from similar rate of CRC deaths in their lifetime [16].
Regarding the mechanism behind the gender differences of CRC, Hartman et al. [126] inves-
tigated the molecular function of ER-β in colon cancer cells, focusing on cell cycle regulation. 
They concluded that ER-β inhibits proliferation and tumor growth of colon cancer cells by 
regulating G1-phase cell cycle genes. Furthermore, this ER-β-mediated cell cycle repression 
is dependent on functional estrogen response element (ERE) binding. To dissect the pro-
cesses that ER-β mediates and to investigate cell-specific mechanisms, Edvardsson et al. [127] 
reexpressed ER-β in three colorectal cancer cell lines (SW480, HT29, and HCT-116) and per-
formed genome-wide expression studies in combination with gene-pathway analyses and 
cross correlation to ER-β-chromatin-binding sites [127]. Overrepresentation analysis of func-
tional classes indicated that the same biological themes, including apoptosis, cell differentia-
tion, and regulation of the cell cycle, were affected in all three cell lines [127]. ER-β-mediated 
downregulation of IL-6 has an important impact on inflammation process involved in colon 
carcinogenesis. The influence of ER-β on apoptosis was further explored using functional 
studies, which suggested an increased DNA repair capacity. Edvardsson et al. propose that 
enhancing ER-β action has potential as a novel therapeutic approach for prevention and/or 
treatment of colon cancer [127].
It has been established that postmenopausal hormone replacement therapy (HRT) is associ-
ated with decreased incidence and death rate of colon cancer in both epidemiologic [141, 
142] and intervention [142, 143] trials. Additional data suggest that this action may, at least 
in part, be mediated through VDR signaling. RT-PCR results confirmed that estrogen admin-
istration increased mRNA expression of VDR as well as of a downstream target of vitamin 
D action, E-cadherin [140]. Besides HRT, high estrogen content of soy is implicated to be 
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 protective against colorectal cancer; however, evidence suggests that higher soy consumption 
is protective against colon cancer only in women [144]. The use of estrogens for prevention of 
colon cancer is an attractive concept in women; however, the increased rates of cardiovascular 
events with HRT limit the use of these agents in clinical practice [118].
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